Investor Relations
5Q Spectra Corporation is committed to maintaining the highest standards of transparency, governance, and shareholder communication. Our Investor Relations function provides timely, accurate, and consistent information to investors, analysts, and other stakeholders.
We welcome inquiries regarding our business, financial performance, strategic direction, and capital markets activities.
Contact Investor Relations
Team 5Q Spectra Corporation
Email: investor@5qspectra.com
Phone: 1-250-558-9639
Corporate Headquarters
5Q Spectra Corporation
Address
1208 W Pender St #300,
Vancouver, BC V6E 0A7
Investor Inquiries
For inquiries related to:
- Financial results and reporting
- Strategic partnerships and corporate development
- Capital markets activity (PIPE, SPAC, IPO readiness)
- Shareholder communications
- Analyst coverage and institutional engagement
Please contact our Investor Relations team at: investor@5qspectra.com
Media & Press Inquiries
For media, press, or public relations requests, please contact: info@5qspectra.com
Governance & Disclosures
5Q Spectra Corporation adheres to applicable
securities laws and regulations, including Regulation FD. Material information is disclosed through appropriate public channels, including press releases and filings with the U.S. Securities and Exchange Commission (SEC), where applicable.
Forward-Looking Statements
This website may contain forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Investors are cautioned not to place undue reliance on these statements.
Stay Updated
To receive updates on financial results, press releases, and corporate announcements, please subscribe.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.